TheMotleyFool
· Jan 9, 2025, 12:15 · 1 min read
This Unpopular Dividend Stock Is a Buy
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6%
← Previous article
3 Ultra-Reliable Dividend King Stocks That Should Increase Their Payouts to All-Time Highs in 2025, Even if There's a Stock Market Sell-Off
Next article →
Prediction: 2 Stocks That'll Be Worth More Than Nvidia 10 Years From Now
Comments
The discussion is visible to sharewise members.